Keith Knutson, PhDMayo Clinic Jacksonville2020 Cookie Laughlin Pilot Study Award Combination Th17-inducing vaccination and immune checkpoint blockade for ovarian cancer treatment Several types of immunotherapies that use the person’s own immune system to attack foreign “cancer” cells while leaving normal cells alone are being tested in ovarian cancer. Using immunotherapy to activate an immune pathway […]
Read More
Kwan Ho Tang, PhDNew York UniversityNew York, NY, United States 2019 Scientific Scholar Award Research in Focus: Novel therapies to treat ovarian cancer Targeting SHP2 and MEK in High-Grade Serous Ovarian Cancer High-grade serous ovarian cancer is the most lethal gynecological disease. Dr. Tang and colleagues have shown in that a combination treatment of SHP2 inhibitor […]
Read More
Erin George, MDUniversity of Pennsylvania2019 Lynda’s Fund Scholar Award Strategies to optimize drug tolerability without compromising efficacy Most women with ovarian cancer present with advanced stage disease. Large surgeries and toxic chemotherapies are the mainstay of treatment and, despite advances in medicine, most ovarian cancers return. Every tumor is unique in its biology, allowing for […]
Read More
Sarah Beth Gitto, PhDUniversity of Pennsylvania2019 Scientific Scholar Award Priming the TME with anti-VEGF to enhance the efficacy of dual checkpoint inhibition in PARPi-resistant OC Recent studies have shown that the use of the PARP inhibitor olaparib increases survival of ovarian cancer. Unfortunately, most patients will become resistant to PARP inhibitors, thus novel treatment strategies […]
Read More
Elizabeth Smith, PhDFox Chase Cancer Center Suppression of cyclooxygenase in prevention of menopausal gonadotropin-stimulated ovarian cancer risk The risk of developing ovarian cancer increases rapidly in the peri- and post-menopausal periods, when ovulation ceases but the reproductive gonadotropin hormones are elevated. These gonadotropins can induce expression of certain enzymes which stimulate an inflammation-like condition that […]
Read More
Robert Jaffe, MDUniversity of California San Francisco Inhibition of Telomerase to Treat Advanced Ovarian Cancer Telomerase is an enzyme that maintains and protects the ends of chromosomes, the telomeres. While telomerase is constrained in many normal adult cells, a majority of cancers appear to depend on active telomerase for their growth, making this enzyme an […]
Read More
Terry Van Dyke, PhD and Vickie Bae-Jump, MD, PhDThe University of North Carolina at Chapel Hill A Pathway to Therapeutic Treatment and Early Detection of Ovarian Cancer This project will compare global gene expression patterns across human and a novel genetically engineered mouse model of epithelial ovarian cancer in order to identify relevant molecular pathways […]
Read More
Ingegerd Hellstrom, MD, PhDUniversity of Washington Silencing TGFbeta to increase the immunogenicity of ovarian carcinoma cells This study aims to improve a woman’s prognosis by adding a therapeutic vaccination to encourage the body to mount an anti-tumor response using the secreted growth regulatory protein TGFβ (transforming growth factor). Dr. Hellstrom has shown that a mouse […]
Read More
Henning Boldt, PhDMayo Clinic The role of pregnancy-associated plasma protein-A (PAPP-A) in ovarian cancer PAPP-A is a protein that has been shown to reduce tumor incidence and burden. Using a PAPP-A mouse model, Dr. Boldt will examine the development of growth of ovarian cancer and the immune response. The results will provide insight into the […]
Read More
Andre Lieber, MD, PhDFred Hutchinson Cancer Research Center Clonality Analysis in Ovarian Cancer In preliminary studies, Dr. Lieber’s laboratory has identified new markers for ovarian cancer ovca stem cells. In this new study, his team will continue to address the concept of ovarian cancer stem cells and the phenotypic plasticity of ovarian cancer cells. Dr. […]
Read More